Intriguingly, ruxolitinib, a JAK/STAT inhibitor, which is known to inhibit pSTAT3 in ovarian cancer cells (Han et al., 2018), was recently evaluated in a phase I/II clinical trial in combination with frontline carboplatin and paclitaxel chemotherapy (NRG-GY007, NCT02713386) (Landen et al., 2022). The gene discussed is SOAT1; the disease is ovarian carcinoma.